2023
In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer
Lu L, Ma W, Johnson C, Khan S, Irwin M, Pusztai L. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. Vaccine 2023, 41: 2073-2083. PMID: 36813666, PMCID: PMC10064809, DOI: 10.1016/j.vaccine.2023.02.048.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmCA-125 AntigenCancer VaccinesEpitopes, T-LymphocyteFemaleHumansMRNA VaccinesOvarian NeoplasmsConceptsMRNA vaccinesOvarian cancerT cell responsesMutation-derived neoantigensT cell epitopesSARS-CoV-2Multiple neoantigensCytotoxic CD8Dendritic cellsCA 125Cancer vaccinesPatient survivalImmune responseCell epitopesNeoepitope peptidesNeoantigensVaccineCell responsesCancerBreastReverse vaccinologyCD8CD40LIFNNeoepitopes
2017
Artificial human antigen‐presenting cells are superior to dendritic cells at inducing cytotoxic T‐cell responses
Li H, Shao S, Cai J, Burner D, Lu L, Chen Q, Minev B, Ma W. Artificial human antigen‐presenting cells are superior to dendritic cells at inducing cytotoxic T‐cell responses. Immunology 2017, 152: 462-471. PMID: 28664991, PMCID: PMC5629434, DOI: 10.1111/imm.12783.Peer-Reviewed Original ResearchMeSH KeywordsAntigen PresentationCancer VaccinesCell SurvivalCytotoxicity, ImmunologicDelayed-Action PreparationsDendritic CellsDrug CompoundingDrug LiberationHumansInhibitor of Apoptosis ProteinsKineticsLactic AcidLipopolysaccharidesMART-1 AntigenMCF-7 CellsNanoparticlesNeoplasmsPeptide FragmentsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerSolubilitySurvivinT-Lymphocytes, CytotoxicConceptsArtificial antigen-presenting cellsCytotoxic T lymphocytesT cell responsesDendritic cellsAntigen-presenting cellsTumor antigenic peptidesCTL responsesMature DCsT cellsAntigen-specific cytotoxic T lymphocytesAntigen-specific CTL responsesHuman antigen-presenting cellsCytotoxic T cell responsesHuman immature dendritic cellsEffective T cell responsesAntigenic peptidesEffective CTL responsesTumor antigen presentationCancer cellsImmature dendritic cellsMature dendritic cellsT-cell immunotherapyMHC class IMHC class I-peptide complexesWarrants further assessment